Table 6

Risk of prevalent disease, by supplement user group.

Outcome

Cases: n/(%) **

OR*

95% CI*

Diabetes

Multiple Supp users

8/(2.9)

0.27

0.12–0.59

Single Supp users

23/(11.1)

1.11

0.74–1.67

No Supp users

70/(8.5)

1.00

Coronary Heart Disease

Multiple Supp users

14/(5.0)

0.48

0.22–1.09

Single Supp users

17/(7.1)

1.08

0.52–2.25

No Supp users

47/(5.6)

1.00

Heart Attack

Multiple Supp users

7/(2.5)

0.51

0.18–1.41

Single Supp users

16/(7.6)

1.76

0.90–3.42

No Supp users

44/(4.4)

1.00

Angina

Multiple Supp users

6/(2.2)

0.41

0.14–1.18

Single Supp users

12/(6.8)

1.71

0.82–3.59

No Supp users

35/(4.7)

1.00

Congestive Heart Failure

Multiple Supp users

4/(1.4)

0.73

0.18–2.95

Single Supp users

9/(2.8)

0.88

0.26–2.97

No Supp users

31/(3.5)

1.00

Stroke

Multiple Supp users

5/(1.8)

1.42

0.39–5.17

Single Supp users

6/(2.6)

1.26

0.34–4.67

No Supp users

29/(2.5)

1.00

Arthritis

Multiple Supp users

88/(31.7)

1.00

0.69–1.46

Single Supp users

71/(31.8)

1.23

0.77–1.98

No Supp users

189/(26.7)

1.00

Emphysema

Multiple Supp users

3/(1.1)

0.55

0.09–3.41

Single Supp users

4/(1.8)

0.73

0.32–1.64

No Supp users

23/(2.3)

1.00

Health Status^†

Multiple Supp users

44/(15.8)

0.26

0.17–0.41

Single Supp users

86/(44.4)

0.75

0.45–1.23

No Supp users

302/(50.9)

1.00

* Logistic regression methods were used to estimate odds ratios (OR) with 95% confidence intervals (CI), adjusted for sex, age and age², education, income and income², and body mass index. The referent group for risk estimation was the No Supp group.

** Number of events, weighted percent

^†Self-assessed as 'good, fair, or poor' versus 'excellent or very good.'

Block et al. Nutrition Journal 2007 6:30   doi:10.1186/1475-2891-6-30